A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Data from the wistar institute indicated that this anti-body labeled with iodine-125 would
localized in the tumor cells of high grade gliomas of the brain. the project combines
surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II
trial in this disease entity.